Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 3 publications
Corrigendum to "OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer" [Gynecol Oncol 2025 Jun 197 182-191].
Journal: Gynecologic oncology
Published: November 07, 2025
OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer.
Journal: Gynecologic oncology
Published: April 08, 2025
Phase II study of Vigil® DNA engineered immunotherapy as maintenance in advanced stage ovarian cancer.
Journal: Gynecologic oncology
Published: July 27, 2016
Showing 1-3 of 3
Last Updated: 09/26/2026